NEONATAL RESPIRATORY DISTRESS SYNDROME TREATMENT MARKET ANALYSIS

Market News

Key development-

1. In May 2020, J.K Lon Government Children Hospital (India) launched less invasive surfactant administration treatment (LISA) for neonatal respiratory distress syndrome.
2. In February 2020, Windtree Therapeutics initiated a study on efficacy and safety of Lucinactant for inhalation in preterm neonates 26 -32 weeks of age suffering from neonatal respiratory distress syndrome.
3. In 2018, the Catholic University of Sacred Heart completed clinical trial of a new technique called IN-REC-SUR-E in preterm neonates with respiratory distress syndrome. The treatment involves the Proactant Alfa drug, high frequency oscillating ventilator and neonatal continuous positive air pressure nasal cap.